-
Expands YoY Global Medical Cannabis Net Revenue
1 by 15% to Record $70.5 million
-
Increases International Medical Cannabis Net Revenue
1 by 22% to Record $42.7 million, with leadership positions across key markets
-
Delivers Adjusted EBITDA1 growth of 52%, reaching $15.4 millionĀ
-
Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2
NASDAQ | TSX: ACB
EDMONTON, AB, Nov. 5, 2025 /CNW/ ā Aurora Cannabis Inc. (theĀ āCompanyā or āAuroraā) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.
āAuroraās quarterly performance…


